Skip to main content
Top
Gepubliceerd in: Quality of Life Research 11/2016

23-05-2016

Adaptation and validation of the “tolerability and quality of life” (TOOL) questionnaire in Chinese bipolar patients

Auteurs: Lin Xiao, Yulin Gao, Lili Zhang, Peiyun Chen, Xiaojia Sun, Siyuan Tang

Gepubliceerd in: Quality of Life Research | Uitgave 11/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Background

It is well known that the antipsychotic drugs impact the health-related quality of life (HRQoL) of the bipolar patients. The side effects had been assessed only from the doctors’ perspective and neglected the patients’ subjective feeling. The aim of the study is to validate the specific instrument “tolerability and quality of life” (TOOL) into Chinese to describe and grade the impact of antipsychotic drugs on HRQoL from patients’ view.

Methods

A psychometric study was conducted with euthymic bipolar disorder patients (N = 105) under antipsychotic treatment. The psychometric properties of the TOOL, including internal consistency, retest reliability, concurrent validity, content validity, discriminative validity, item analysis, confirmatory factor analysis and feasibility, were analyzed.

Results

The internal consistency and intraclass correlation coefficient (ICC) were adequate (Cronbach’s alpha = 0.80 and ICC = 0.81). A confirmatory factor analysis (CFA) validated the one-factor model. Significant Spearman’s rank correlations between the TOOL and both Bref QoL.BD (Brief version of Quality of Life in Bipolar Disorder) (r = −0.33, P < 0.01) and UKU (Udvalg for Kliniske Undersogelser side effects scale) (r = 0.13, P < 0.05) were found.

Limitations

Small sample size and no specific self-report instrument in Chinese to evaluate the criterion validity.

Conclusions

TOOL appears to be a reliable and valid measure to assess the impact of adverse events of antipsychotic drugs on HRQoL from the patients’ perspective.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Buckley, P. F. (2008). Update on the etiology and treatment of schizophrenia and bipolar disorder. CNS Spectrums, 13(Suppl 1), 3–10. Buckley, P. F. (2008). Update on the etiology and treatment of schizophrenia and bipolar disorder. CNS Spectrums, 13(Suppl 1), 3–10.
2.
go back to reference Edwards, S. J., & Smith, C. J. (2009). Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials. Clinical Therapeutics, 31, 1345–1359.CrossRefPubMed Edwards, S. J., & Smith, C. J. (2009). Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials. Clinical Therapeutics, 31, 1345–1359.CrossRefPubMed
3.
go back to reference Elmslie, J. L., Silverstone, J. J., Mann, J. I., Williams, S. M., & Romans, S. E. (2000). Prevalence of overweight and obesity in bipolar patients. Journal of Clinical Psychiatry, 61(3), 179–184.CrossRefPubMed Elmslie, J. L., Silverstone, J. J., Mann, J. I., Williams, S. M., & Romans, S. E. (2000). Prevalence of overweight and obesity in bipolar patients. Journal of Clinical Psychiatry, 61(3), 179–184.CrossRefPubMed
4.
go back to reference Fagiolini, A., Chengappa, K. N., Soreca, I., & Chang, J. (2008). Bipolar disorder and the metabolic syndrome: Causal factors, psychiatric outcomes and economic burden. CNS Drugs, 22(8), 655–669.CrossRefPubMed Fagiolini, A., Chengappa, K. N., Soreca, I., & Chang, J. (2008). Bipolar disorder and the metabolic syndrome: Causal factors, psychiatric outcomes and economic burden. CNS Drugs, 22(8), 655–669.CrossRefPubMed
5.
go back to reference Kolotkin, R. L., Corey, L., & Crosby, R. D. (2008). Impact of obesity on HRQoL in schizophrenia and bipolar disorder. Obesity, 16, 749–754.CrossRefPubMed Kolotkin, R. L., Corey, L., & Crosby, R. D. (2008). Impact of obesity on HRQoL in schizophrenia and bipolar disorder. Obesity, 16, 749–754.CrossRefPubMed
6.
go back to reference Berk, M., & Berk, L. (2003). Mood stabilizers and treatment adherence in bipolar disorder: Addressing adverse events. Annals of Clinical Psychiatry, 15(3), 217–224.CrossRefPubMed Berk, M., & Berk, L. (2003). Mood stabilizers and treatment adherence in bipolar disorder: Addressing adverse events. Annals of Clinical Psychiatry, 15(3), 217–224.CrossRefPubMed
7.
go back to reference Chue, P., & Kovacs, C. S. (2003). Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: Prevalence, monitoring and management. Bipolar Disorders, 5(Suppl 2), 62–79.CrossRefPubMed Chue, P., & Kovacs, C. S. (2003). Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: Prevalence, monitoring and management. Bipolar Disorders, 5(Suppl 2), 62–79.CrossRefPubMed
8.
go back to reference Johnson, F. R., Ozdemir, S., Manjunath, R., Hauber, A. B., Burch, S. P., & Thompson, T. R. (2007). Factors that affect adherence to bipolar disorder treatments: A stated-preference approach. Medical Care, 45(6), 545–552.CrossRefPubMed Johnson, F. R., Ozdemir, S., Manjunath, R., Hauber, A. B., Burch, S. P., & Thompson, T. R. (2007). Factors that affect adherence to bipolar disorder treatments: A stated-preference approach. Medical Care, 45(6), 545–552.CrossRefPubMed
9.
go back to reference Sachs, G. S. (2003). Unmet clinical needs in bipolar disorder. Journal of Clinical Psychopharmacology, 23(Suppl 1), S2–S8.PubMed Sachs, G. S. (2003). Unmet clinical needs in bipolar disorder. Journal of Clinical Psychopharmacology, 23(Suppl 1), S2–S8.PubMed
10.
go back to reference Lingam, R., & Scott, J. (2002). Treatment non-adherence in affective disorders. Acta Psychiatrica Scand., 105(3), 164–172.CrossRef Lingam, R., & Scott, J. (2002). Treatment non-adherence in affective disorders. Acta Psychiatrica Scand., 105(3), 164–172.CrossRef
11.
go back to reference Endicott, J., Paulsson, B., Gustafsson, U., Schioler, H., & Hassan, M. (2008). Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep. Journal of Affective Disorders, 111(2–3), 306–319.CrossRefPubMed Endicott, J., Paulsson, B., Gustafsson, U., Schioler, H., & Hassan, M. (2008). Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep. Journal of Affective Disorders, 111(2–3), 306–319.CrossRefPubMed
12.
go back to reference Yen, C. F., Cheng, C. P., Huang, C. F., Yen, J. Y., Ko, C. H., & Chen, C. S. (2008). Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission. Bipolar Disorders, 10(5), 617–624.CrossRefPubMed Yen, C. F., Cheng, C. P., Huang, C. F., Yen, J. Y., Ko, C. H., & Chen, C. S. (2008). Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission. Bipolar Disorders, 10(5), 617–624.CrossRefPubMed
13.
go back to reference Awad, A. G., Hogan, T. P., Voruganti, L. N., & Heslegrave, R. J. (1995). Patients’ subjective experiences on antipsychotic medications: Implications for outcome and quality of life. International Clinical Psychopharmacology, 10, 123–132.PubMed Awad, A. G., Hogan, T. P., Voruganti, L. N., & Heslegrave, R. J. (1995). Patients’ subjective experiences on antipsychotic medications: Implications for outcome and quality of life. International Clinical Psychopharmacology, 10, 123–132.PubMed
14.
go back to reference Ritsner, M., Modai, I., Endicott, J., Rivkin, O., Nechamkin, Y., Barak, P., et al. (2000). Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. Journal of Clinical Psychiatry, 61(11), 880–889.CrossRefPubMed Ritsner, M., Modai, I., Endicott, J., Rivkin, O., Nechamkin, Y., Barak, P., et al. (2000). Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. Journal of Clinical Psychiatry, 61(11), 880–889.CrossRefPubMed
15.
go back to reference Reine, G., Lancon, C., Di, T. S., Sapin, C., & Auquier, P. (2003). Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatrica Scandinavica, 108(4), 297–303.CrossRefPubMed Reine, G., Lancon, C., Di, T. S., Sapin, C., & Auquier, P. (2003). Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatrica Scandinavica, 108(4), 297–303.CrossRefPubMed
16.
go back to reference Taksh, U. (2006). A critical review of rating scales in the assessment of movement disorders in schizophrenia. Current Drug Targets, 7(9), 1225–1229.CrossRefPubMed Taksh, U. (2006). A critical review of rating scales in the assessment of movement disorders in schizophrenia. Current Drug Targets, 7(9), 1225–1229.CrossRefPubMed
17.
go back to reference Lingjaerde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica, 334, 1–100.CrossRefPubMed Lingjaerde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica, 334, 1–100.CrossRefPubMed
18.
go back to reference Thornicroft, G., & Tansella, M. (2005). Growing recognition of the importance of service user involvement in mental health service planning and evaluation. Epidemiologia e Psichiatria Sociale, 14(1), 1–3.CrossRefPubMed Thornicroft, G., & Tansella, M. (2005). Growing recognition of the importance of service user involvement in mental health service planning and evaluation. Epidemiologia e Psichiatria Sociale, 14(1), 1–3.CrossRefPubMed
19.
go back to reference Montejo, A. L. (2008). Prolactin awareness: An essential consideration for physical health in schizophrenia. European Neuropsychopharmacology, 18(Suppl 2), S108–S114.CrossRefPubMed Montejo, A. L. (2008). Prolactin awareness: An essential consideration for physical health in schizophrenia. European Neuropsychopharmacology, 18(Suppl 2), S108–S114.CrossRefPubMed
20.
go back to reference Montejo, A. L., Correas-Lauffer, J., Mauriño, J., Villa, G., Rebollo, P., Díez, T., & Cordero, L. (2011). Estimation of a multiattribute utility function for the Spanish version of the TOOL questionnaire. Value in Health, 14(4), 564–570.CrossRefPubMed Montejo, A. L., Correas-Lauffer, J., Mauriño, J., Villa, G., Rebollo, P., Díez, T., & Cordero, L. (2011). Estimation of a multiattribute utility function for the Spanish version of the TOOL questionnaire. Value in Health, 14(4), 564–570.CrossRefPubMed
21.
go back to reference Lindstrom, E., Jonsson, L., & Berntsson, A. (2009). A patient perspective on side effects of antipsychotic therapy: The TOOL instrument. Value in Health, 12(7), A361.CrossRef Lindstrom, E., Jonsson, L., & Berntsson, A. (2009). A patient perspective on side effects of antipsychotic therapy: The TOOL instrument. Value in Health, 12(7), A361.CrossRef
22.
go back to reference Jonsson, L., Lang, A., & Lindstrom, E. (2009). TOOL: Multi-attribute utility function reflecting patient experience of side effects to antipsychotic therapy. Value in Health, 12(7), A361.CrossRef Jonsson, L., Lang, A., & Lindstrom, E. (2009). TOOL: Multi-attribute utility function reflecting patient experience of side effects to antipsychotic therapy. Value in Health, 12(7), A361.CrossRef
23.
go back to reference Montejo, A. L., Lauffer, J. C., Cuervo, J., Rebollo, P., Cordero, L., Diez, T., & Maurino, J. (2011). Validation of a specific measure to assess health related quality of life in patients with schizophrenia and bipolar disorder: The ‘Tolerability and quality of life’ (TOOL) questionnaire. Annals of General Psychiatry, 10(1), 6.CrossRefPubMedPubMedCentral Montejo, A. L., Lauffer, J. C., Cuervo, J., Rebollo, P., Cordero, L., Diez, T., & Maurino, J. (2011). Validation of a specific measure to assess health related quality of life in patients with schizophrenia and bipolar disorder: The ‘Tolerability and quality of life’ (TOOL) questionnaire. Annals of General Psychiatry, 10(1), 6.CrossRefPubMedPubMedCentral
24.
go back to reference Maurino, J., Cordero, L., Montejo, A. L., Correas-Lauffer, J., Cuervo, J., Rebollo, P., et al. (2009). The Spanish version of the TOOL questionnaire: Validation of a specific measure to evaluate health related quality of life in patients with schizophrenia and bipolar disorder. Value in Health, 12(7), A362.CrossRef Maurino, J., Cordero, L., Montejo, A. L., Correas-Lauffer, J., Cuervo, J., Rebollo, P., et al. (2009). The Spanish version of the TOOL questionnaire: Validation of a specific measure to evaluate health related quality of life in patients with schizophrenia and bipolar disorder. Value in Health, 12(7), A362.CrossRef
25.
go back to reference Maurino, J., Cordero, L., Montejo, A., Rebollo, P., & Cuervo, J. (2008). The Spanish version of the TOOL questionnaire: A useful measure for evaluating the HRQoL and utilities from schizophrenic and bipolar patients. Value in Health, 11(6), A593.CrossRef Maurino, J., Cordero, L., Montejo, A., Rebollo, P., & Cuervo, J. (2008). The Spanish version of the TOOL questionnaire: A useful measure for evaluating the HRQoL and utilities from schizophrenic and bipolar patients. Value in Health, 11(6), A593.CrossRef
26.
go back to reference Gandek, B., & Ware, J. E. (1998). Methods for validating and norming translations of health status questionnaires: The IQOLA project approach. Journal of Clinical Epidemiology, 51(11), 953–959.CrossRefPubMed Gandek, B., & Ware, J. E. (1998). Methods for validating and norming translations of health status questionnaires: The IQOLA project approach. Journal of Clinical Epidemiology, 51(11), 953–959.CrossRefPubMed
28.
go back to reference Bech. (1979). The Bech-Rafaelsen Mania Scale and Hamilton Depression Scale. Acta Psychiatrica Scandinavica, 59, 420–429.CrossRefPubMed Bech. (1979). The Bech-Rafaelsen Mania Scale and Hamilton Depression Scale. Acta Psychiatrica Scandinavica, 59, 420–429.CrossRefPubMed
29.
go back to reference Zhang, Z. J. (2001). Hamilton Depression Scale. Chinese Journal of Behavioral Medical Science, 10, 134–135. Zhang, Z. J. (2001). Hamilton Depression Scale. Chinese Journal of Behavioral Medical Science, 10, 134–135.
30.
go back to reference Cui, S. (1985). Bech-Rafaelsen Mania Rating Scale for the assessment of manic patients. Chinese Journal of Nervous and Mental Diseases, 18, 267–269. Cui, S. (1985). Bech-Rafaelsen Mania Rating Scale for the assessment of manic patients. Chinese Journal of Nervous and Mental Diseases, 18, 267–269.
31.
go back to reference Michalak, E. E., Murray, G., & CREST.BD. (2010). Development of the QoL.BD: A disorder specific scale to assess quality of life in bipolar disorder. Bipolar Disorders, 12(7), 727–740.CrossRefPubMed Michalak, E. E., Murray, G., & CREST.BD. (2010). Development of the QoL.BD: A disorder specific scale to assess quality of life in bipolar disorder. Bipolar Disorders, 12(7), 727–740.CrossRefPubMed
32.
go back to reference Xiao, L., Gao, Y. L., Zhang, L. L., Chen, P. Y., Sun, X. J., & Tang, S. Y. (2016). Validity and reliability of the Brief version of Quality of Life in Bipolar Disorder (Bref QoL.BD) among Chinese bipolar patients. Journal of Affective Disorders, 193, 66–72.CrossRefPubMed Xiao, L., Gao, Y. L., Zhang, L. L., Chen, P. Y., Sun, X. J., & Tang, S. Y. (2016). Validity and reliability of the Brief version of Quality of Life in Bipolar Disorder (Bref QoL.BD) among Chinese bipolar patients. Journal of Affective Disorders, 193, 66–72.CrossRefPubMed
33.
go back to reference Polit, D. F., & Beck, C. T. (2006). The content validity index: Are you sure you know what’s being reported? critique and recommendations. Research in Nursing & Health, 29(5), 489–497. (Chinese journal).CrossRef Polit, D. F., & Beck, C. T. (2006). The content validity index: Are you sure you know what’s being reported? critique and recommendations. Research in Nursing & Health, 29(5), 489–497. (Chinese journal).CrossRef
34.
go back to reference Shi, J. C., Mo, X. K., & Sun, Z. Q. (2012). Content validity index in scale development. Journal of Central South University, 37(2), 152–155. (Chinese journal). Shi, J. C., Mo, X. K., & Sun, Z. Q. (2012). Content validity index in scale development. Journal of Central South University, 37(2), 152–155. (Chinese journal).
35.
go back to reference Joreskog, K. G., & Sorbom, D. (1996). LISREL 8: User’s reference guide. Chicago: Scientific Software International. Joreskog, K. G., & Sorbom, D. (1996). LISREL 8: User’s reference guide. Chicago: Scientific Software International.
36.
go back to reference Kelloway, E. K. (1998). Using LISREL for structural equation modeling: A researcher’s guide. Thousand Oaks, CA: SAGE. Kelloway, E. K. (1998). Using LISREL for structural equation modeling: A researcher’s guide. Thousand Oaks, CA: SAGE.
37.
go back to reference Kline, R. B. (1998). Principals and practice of structural equation modeling. New York, NY: Guilford. Kline, R. B. (1998). Principals and practice of structural equation modeling. New York, NY: Guilford.
39.
go back to reference Bollen, K. A. (1989). Structural equation with latent variables. New York, NY: Wiley.CrossRef Bollen, K. A. (1989). Structural equation with latent variables. New York, NY: Wiley.CrossRef
40.
go back to reference Bonnin, C. M., Sanchez-Moreno, J., Martinez-Aran, A., Sole, B., Reinares, M., Rosa, A. R., et al. (2012). Subthreshold symptoms in bipolar disorder: Impact on neurocognition, quality of life and disability. Journal of Affective Disorders, 136(3), 650–659.CrossRefPubMed Bonnin, C. M., Sanchez-Moreno, J., Martinez-Aran, A., Sole, B., Reinares, M., Rosa, A. R., et al. (2012). Subthreshold symptoms in bipolar disorder: Impact on neurocognition, quality of life and disability. Journal of Affective Disorders, 136(3), 650–659.CrossRefPubMed
41.
go back to reference Cochran, W. G. (1952). The χ2 test of goodness of fit. The Annals of Mathematical Statistics, 23(3), 315–345.CrossRef Cochran, W. G. (1952). The χ2 test of goodness of fit. The Annals of Mathematical Statistics, 23(3), 315–345.CrossRef
42.
go back to reference Michalak, E. E., Yatham, L. N., & Lam, R. W. (2005). Quality of life in bipolar disorder: A review of the literature. Health and Quality of Life Outcomes, 3, 72.CrossRefPubMedPubMedCentral Michalak, E. E., Yatham, L. N., & Lam, R. W. (2005). Quality of life in bipolar disorder: A review of the literature. Health and Quality of Life Outcomes, 3, 72.CrossRefPubMedPubMedCentral
43.
go back to reference Morselli, P. L., Elgie, R., & Cesana, B. M. (2004). GAMIAN-Europe/BEAM survey II: Cross-national analysis of unemployment, family history, treatment satisfaction and impact of the bipolar disorder on life style. Bipolar Disorders, 6(6), 487–497.CrossRefPubMed Morselli, P. L., Elgie, R., & Cesana, B. M. (2004). GAMIAN-Europe/BEAM survey II: Cross-national analysis of unemployment, family history, treatment satisfaction and impact of the bipolar disorder on life style. Bipolar Disorders, 6(6), 487–497.CrossRefPubMed
44.
go back to reference Endicott, J., Rajagopalan, K., Minkwitz, M., & Macfadden, W. (2007). BOLDER Study Group. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: Improvements in quality of life. International Clinical Psychopharmacology, 22, 29–37.CrossRefPubMed Endicott, J., Rajagopalan, K., Minkwitz, M., & Macfadden, W. (2007). BOLDER Study Group. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: Improvements in quality of life. International Clinical Psychopharmacology, 22, 29–37.CrossRefPubMed
45.
go back to reference Vornik, L. A., & Hirschfeld, R. M. (2005). Bipolar disorder: Quality of life and the impact of atypical antipsychotics. The American Journal of Managed Care, 11(Suppl. 9), 275–280. Vornik, L. A., & Hirschfeld, R. M. (2005). Bipolar disorder: Quality of life and the impact of atypical antipsychotics. The American Journal of Managed Care, 11(Suppl. 9), 275–280.
46.
go back to reference Perkins, D. O., Gu, H., Weiden, P. J., McEvoy, J. P., Hamer, R. M., & Lieberman, J. A. (2008). Predictors of treatment discontinuation and medication non-adherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study. Journal of Clinical Psychiatry, 69(1), 106–113.CrossRefPubMed Perkins, D. O., Gu, H., Weiden, P. J., McEvoy, J. P., Hamer, R. M., & Lieberman, J. A. (2008). Predictors of treatment discontinuation and medication non-adherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study. Journal of Clinical Psychiatry, 69(1), 106–113.CrossRefPubMed
47.
go back to reference Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., & Mukherjee, J. (2008). Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: Direct utility elicitation. Health and Quality of Life Outcomes, 6, 105.CrossRefPubMedPubMedCentral Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., & Mukherjee, J. (2008). Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: Direct utility elicitation. Health and Quality of Life Outcomes, 6, 105.CrossRefPubMedPubMedCentral
48.
go back to reference Hayhurst, H., Palmer, S., Abbott, R., Johnson, T., & Scott, J. (2006). Measuring health-related quality of life in bipolar disorder: Relationship of the EuroQol (EQ-5D) to condition-specific measures. Quality of Life Research, 15(7), 1271–1280.CrossRefPubMed Hayhurst, H., Palmer, S., Abbott, R., Johnson, T., & Scott, J. (2006). Measuring health-related quality of life in bipolar disorder: Relationship of the EuroQol (EQ-5D) to condition-specific measures. Quality of Life Research, 15(7), 1271–1280.CrossRefPubMed
Metagegevens
Titel
Adaptation and validation of the “tolerability and quality of life” (TOOL) questionnaire in Chinese bipolar patients
Auteurs
Lin Xiao
Yulin Gao
Lili Zhang
Peiyun Chen
Xiaojia Sun
Siyuan Tang
Publicatiedatum
23-05-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 11/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-016-1319-1

Andere artikelen Uitgave 11/2016

Quality of Life Research 11/2016 Naar de uitgave